Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany.
COVID-19
IgA
IgG
SARS-CoV-2
herd immunity
immunoglobulin
seroprevalence
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
06
2020
accepted:
27
08
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
A vast majority of COVID-19 cases present with mild or moderate symptoms. The study region is in an urban and well-defined environment in a low-incidence region in Northern Germany. In the present study, we explored the dynamics of the antibody response with respect to onset, level and duration in patients with confirmed SARS-CoV-2 infection. Anti-SARS-CoV-2 IgG and IgA were detected by automated enzyme-linked immunosorbent assay (ELISA) of SARS-CoV-2 infected patients monitored by the Health Protection Authority. This explorative monocentric study shows IgA and IgG antibody profiles from 118 patients with self-reported mild to moderate, or no COVID-19 related symptoms after laboratory-confirmed infection with SARS-CoV-2. We found that 21.7% and 18.1% of patients were seronegative for IgA or IgG, respectively. Clinically, most of the seronegative patients showed no to only moderate symptoms. With regard to antibody profiling 82% of all patients developed sustainable antibodies (IgG) and 78% (IgA) 3 weeks or later after the infection. Our data indicate that antibody-positivity is a useful indicator of a previous SARS-CoV-2 infection. Negative antibodies do not rule out SARS-CoV-2 infection. Future studies are needed to determine the functionality of the antibodies in terms of neutralization capacity leading to personal protection and prevention ability to transmit the virus as well as to protect after vaccination.
Identifiants
pubmed: 33072707
doi: 10.3389/fpubh.2020.570543
pmc: PMC7536334
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Pagination
570543Informations de copyright
Copyright © 2020 Solbach, Schiffner, Backhaus, Burger, Staiger, Tiemer, Bobrowski, Hutchings and Mischnik.
Références
N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Infect. 2020 Aug;81(2):318-356
pubmed: 32360497
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet Infect Dis. 2020 Sep;20(9):e245-e249
pubmed: 32687805
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Clin Infect Dis. 2020 Apr 19;:
pubmed: 32306047
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196
J Med Virol. 2020 May 8;:
pubmed: 32383174
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Med Virol. 2020 Apr 20;:
pubmed: 32311142
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Emerg Infect Dis. 2020 Aug;26(8):1935-1937
pubmed: 32392125
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Lancet Infect Dis. 2020 Aug;20(8):920-928
pubmed: 32422201
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347